Scientific Reports (Jul 2023)
A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)
- Thomas Starkey,
- Maria C. Ionescu,
- Michael Tilby,
- Martin Little,
- Emma Burke,
- Matthew W. Fittall,
- Sam Khan,
- Justin K. H. Liu,
- James R. Platt,
- Rosie Mew,
- Arvind R. Tripathy,
- Isabella Watts,
- Sophie Therese Williams,
- Nathan Appanna,
- Youssra Al-Hajji,
- Matthew Barnard,
- Liza Benny,
- Alexander Burnett,
- Jola Bytyci,
- Emma L. Cattell,
- Vinton Cheng,
- James J. Clark,
- Leonie Eastlake,
- Kate Gerrand,
- Qamar Ghafoor,
- Simon Grumett,
- Catherine Harper-Wynne,
- Rachel Kahn,
- Alvin J. X. Lee,
- Oliver Lomas,
- Anna Lydon,
- Hayley Mckenzie,
- NCRI Consumer Forum,
- Hari Panneerselvam,
- Jennifer S. Pascoe,
- Grisma Patel,
- Vijay Patel,
- Vanessa A. Potter,
- Amelia Randle,
- Anne S. Rigg,
- Tim M. Robinson,
- Rebecca Roylance,
- Tom W. Roques,
- Stefan Rozmanowski,
- René L. Roux,
- Ketan Shah,
- Remarez Sheehan,
- Martin Sintler,
- Sanskriti Swarup,
- Harriet Taylor,
- Tania Tillett,
- Mark Tuthill,
- Sarah Williams,
- Yuxin Ying,
- Andrew Beggs,
- Tim Iveson,
- Siow Ming Lee,
- Gary Middleton,
- Mark Middleton,
- Andrew Protheroe,
- Tom Fowler,
- Peter Johnson,
- Lennard Y. W. Lee
Affiliations
- Thomas Starkey
- Institute of Cancer and Genomic Sciences, University of Birmingham
- Maria C. Ionescu
- UK Health Security Agency
- Michael Tilby
- University Hospitals Birmingham NHS Foundation Trust
- Martin Little
- Oxford University Hospitals NHS Trust
- Emma Burke
- Oxford University Hospitals NHS Trust
- Matthew W. Fittall
- Cancer Institute, University College London
- Sam Khan
- University of Leicester
- Justin K. H. Liu
- University of Leeds
- James R. Platt
- Leeds Institute of Medical Research at St James’s
- Rosie Mew
- Torbay and South Devon NHS Foundation Trust
- Arvind R. Tripathy
- Queen Elizabeth Hospital Birmingham
- Isabella Watts
- Royal Free London NHS Foundation Trust
- Sophie Therese Williams
- University of Sheffield
- Nathan Appanna
- Oxford Medical School, University of Oxford
- Youssra Al-Hajji
- Birmingham Medical School, University of Birmingham
- Matthew Barnard
- UK Health Security Agency
- Liza Benny
- UK Health Security Agency
- Alexander Burnett
- Weston Park Cancer Centre
- Jola Bytyci
- Department of Oncology, University of Oxford
- Emma L. Cattell
- Taunton and Somerset NHS Foundation Trust
- Vinton Cheng
- University of Leeds
- James J. Clark
- Imperial College London
- Leonie Eastlake
- Royal Cornwall Hospital Trust
- Kate Gerrand
- UK Health Security Agency
- Qamar Ghafoor
- University Hospitals Birmingham NHS Foundation Trust
- Simon Grumett
- University Hospitals Birmingham NHS Foundation Trust
- Catherine Harper-Wynne
- Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust
- Rachel Kahn
- Blood Cancer UK
- Alvin J. X. Lee
- University College London
- Oliver Lomas
- Oxford University Hospitals NHS Trust
- Anna Lydon
- Torbay and South Devon NHS Foundation Trust
- Hayley Mckenzie
- University Hospital Southampton NHS Foundation Trust
- NCRI Consumer Forum
- National Cancer Research Institute Consumer Forum
- Hari Panneerselvam
- Wye Valley NHS Trust
- Jennifer S. Pascoe
- University Hospitals Birmingham NHS Foundation Trust
- Grisma Patel
- University College London
- Vijay Patel
- National Health Service
- Vanessa A. Potter
- University Hospitals Coventry and Warwickshire NHS Trust
- Amelia Randle
- Royal College of Physicians
- Anne S. Rigg
- Guy’s and St Thomas’ NHS Foundation Trust
- Tim M. Robinson
- University of Bristol
- Rebecca Roylance
- University College London Hospitals NHS Foundation Trust
- Tom W. Roques
- Norfolk and Norwich University Hospitals NHS Foundation Trust
- Stefan Rozmanowski
- UK Health Security Agency
- René L. Roux
- Oxford University Hospitals NHS Trust
- Ketan Shah
- Oxford University Hospitals NHS Trust
- Remarez Sheehan
- Nuffield Department of Surgical Sciences, University of Oxford
- Martin Sintler
- Sandwell and West Birmingham Hospitals NHS Trust
- Sanskriti Swarup
- Department of Oncology, University of Oxford
- Harriet Taylor
- Oxford Medical School, University of Oxford
- Tania Tillett
- Royal United Hospital Bath NHS Trust
- Mark Tuthill
- Oxford University Hospitals NHS Trust
- Sarah Williams
- University Hospitals Birmingham NHS Foundation Trust
- Yuxin Ying
- Department of Oncology, University of Oxford
- Andrew Beggs
- Institute of Cancer and Genomic Sciences, University of Birmingham
- Tim Iveson
- University Hospital Southampton NHS Foundation Trust
- Siow Ming Lee
- University College London Hospitals NHS Foundation Trust
- Gary Middleton
- Institute of Immunology and Immunotherapy, University of Birmingham
- Mark Middleton
- Department of Oncology, University of Oxford
- Andrew Protheroe
- Churchill Hospital, Oxford University Hospitals NHS Foundation Trust
- Tom Fowler
- UK Health Security Agency
- Peter Johnson
- University of Southampton
- Lennard Y. W. Lee
- Institute of Cancer and Genomic Sciences, University of Birmingham
- DOI
- https://doi.org/10.1038/s41598-023-36990-9
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 8
Abstract
Abstract Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission.
